Key statistics
As of last trade, Mainz Biomed NV (4TO:BER) traded at 0.3345, 16.35% above the 52 week low of 0.2875 set on Aug 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.3345 |
---|---|
High | 0.3345 |
Low | 0.3345 |
Bid | 0.3645 |
Offer | 0.3695 |
Previous close | 0.3255 |
Average volume | 40.38k |
---|---|
Shares outstanding | 21.89m |
Free float | 17.15m |
P/E (TTM) | -- |
Market cap | 8.60m USD |
EPS (TTM) | -1.67 USD |
Data delayed at least 15 minutes, as of Sep 04 2024 07:08 BST.
More ▼
Announcements
- Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
- Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
- Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
- Mainz Biomed Provides Half Year 2024 Corporate Update
- Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
- Mainz Biomed Reports Results of 2024 Annual General Meeting
- Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
- Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
- Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
- Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
More ▼